Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congr

CARLSBAD, Calif., Sept. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What:

Data from Mipomersen's Open-Label Extension Study presented at ESC



When:

Wednesday, September 07, 2011 at 12:00 p.m. ET / 9:00 a.m. PT



Where:

www.isispharm.com



How:

Live on the Internet.  Simply log onto our Web site listed above.





If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…